Seer (NasdaqGS:SEER) FY Conference Transcript

Summary of Seer Inc. Conference Call Company Overview - Company: Seer Inc. - Industry: Tools and diagnostics in the healthcare sector Key Points and Arguments Company Performance and Growth - Seer experienced substantial growth in 2025, with a 67% increase in install base, reaching 82 instruments [5] - Year-over-year consumable volume increased by 70% [5] - Publications from customers rose from approximately 35 to 76, with many appearing in high-impact journals [5] - Seer successfully conducted three population-scale studies using deep unbiased proteomics, with sample sizes of 10,000+ and 20,000+ [6] Product Development and Innovation - Launched the Proteograph ONE Assay in June 2025, which significantly improved operational efficiency by reducing runtime from 8.5 hours to 4.5 hours and increasing throughput to 80 samples per run [6][7] - The company aims for revenue growth of 50% to 100% annually, emphasizing the need to build a market for their product [8] Market Strategy and Customer Engagement - Introduced the Seer Technology Access Center (STAC) to lower barriers for customer adoption, with 50% of the install base in 2025 being previous STAC users [12] - The Strategic Instrument Replacement Program (SIP) allowed customers to test instruments with a significant upfront consumable purchase, leading to a 60% conversion rate from loans to purchases [13] - Addressed bottlenecks in unbiased proteomics through various upgrades, including the Proteograph Analysis Suite [14] Financial Outlook and Market Challenges - Guidance for 2026 anticipates total revenue between $16 million and $18 million, with a growth rate of 3% at the midpoint [9] - The company faces challenges from funding constraints in the academic market and NIH, impacting customer budgets [16][42] - Despite these challenges, discussions with population-scale cohorts are ongoing, indicating potential for future revenue growth [16] Competitive Landscape - Seer claims to have a unique position in the protein enrichment space, with over 200 patents supporting their technology [45] - Competitors are noted to be inferior in performance, as evidenced by customer publications [45] - Seer emphasizes the importance of innovation over competition, focusing on moving the goalpost forward [45] Future Developments - A new detector, purpose-built for deep unbiased proteomics, is expected to change the landscape of the field, with data to be shared in the second half of the year [33][35] - The company remains optimistic about future growth, with a strong belief in the value of their technology and its potential impact on the market [48] Additional Important Insights - The company has maintained a low operational expenditure (OpEx) while investing in innovation, demonstrating financial discipline [37] - The gross margin is currently in the low 50% range, with consumables driving the majority of profitability [18] - Seer is committed to competitive pricing to facilitate adoption, particularly in population studies, while ensuring the value of their offerings is recognized [19] This summary encapsulates the key insights from Seer Inc.'s conference call, highlighting the company's growth, product innovations, market strategies, and future outlook in the diagnostics industry.